Long‐Term Survival With Olaparib Maintenance Therapy in Metastatic Pancreatic Carcinoma of a Patient Harboring Germline BRIP1 and ATM Mutations

Ruemu E. Birhiray, Maya N. Birhiray, Samuel L. Ranger, Vincent L. Flanders · 2025

Read Long‐Term Survival With Olaparib Maintenance Therapy in Metastatic Pancreatic Carcinoma of a Patient Harboring Germline BRIP1 and ATM Mutations by Ruemu E. Birhiray, Maya N. Birhiray, Samuel L. Ranger, Vincent L. Flanders (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12747106.txt.

Description

Ruemu Birhiray and three co-authors report a striking pancreatic cancer case in a 2025 paper. Pancreatic cancer kills about fifty thousand Americans a year and rarely allows long survival. A small subgroup carries inherited DNA repair defects that open a drug door.

The patient, a seventy-two-year-old woman, carried inherited mutations in two repair genes. Those defects leave tumors unable to fix certain DNA damage. After strong chemotherapy she reached complete remission. A maintenance pill that blocks DNA repair in cancer cells has kept her in remission for over forty months. That drug is approved for a related mutation group, not hers. The case argues for widening access to repair-targeted therapy in pancreatic cancer.

Catalog record

CREATORRuemu E. Birhiray, Maya N. Birhiray, Samuel L. Ranger, Vincent L. Flanders
YEAR2025
COLLECTIONPAPERS
FORMATTXT
FILE SIZE15 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC12747106

Browse the full library · About the Tower of Babel